DELIVER G was a retrospective pre-post study of 271 adult patients with type 2 diabetes receiving GLP-1 RA therapy who were insulin-naive prior to subsequent treatment intensification with Gla-300
Available from Accessed 29 January 2024 Ruder K (2023) As semaglutides popularity soars, rare but serious adverse effects are emerging
J Neurochem 101(5)1205-1213 Haroon E, Miller AH, Sanacora G (2017) Inflammation, glutamate, and glia: a trio of trouble in mood disorders
Youre altering your digestion, metabolism, and even brain signaling - all things linked to energy levels
The company will resubmit the Investigational New Drug Application as expeditiously as possible in order to move forward with clinical trials, Hemogenyx CEO Vladislav Sandler said in the same press release
Kaya A, Atabekoglu CS, Kahraman K, et al